HK1179655A1 - 用於治療癌症的嵌合腺病毒 - Google Patents

用於治療癌症的嵌合腺病毒

Info

Publication number
HK1179655A1
HK1179655A1 HK13106822.6A HK13106822A HK1179655A1 HK 1179655 A1 HK1179655 A1 HK 1179655A1 HK 13106822 A HK13106822 A HK 13106822A HK 1179655 A1 HK1179655 A1 HK 1179655A1
Authority
HK
Hong Kong
Prior art keywords
cancer treatment
chimeric adenoviruses
adenoviruses
chimeric
cancer
Prior art date
Application number
HK13106822.6A
Other languages
English (en)
Inventor
保羅．哈登
特麗．赫米斯頓
艾琳．庫恩
Original Assignee
普西奧克瑟斯醫療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 普西奧克瑟斯醫療有限公司 filed Critical 普西奧克瑟斯醫療有限公司
Publication of HK1179655A1 publication Critical patent/HK1179655A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK13106822.6A 2004-05-26 2013-06-09 用於治療癌症的嵌合腺病毒 HK1179655A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57485104P 2004-05-26 2004-05-26

Publications (1)

Publication Number Publication Date
HK1179655A1 true HK1179655A1 (zh) 2013-10-04

Family

ID=35355425

Family Applications (3)

Application Number Title Priority Date Filing Date
HK07112859.8A HK1109421A1 (en) 2004-05-26 2007-11-26 Chimeric adenoviruses for use in cancer treatment
HK13106822.6A HK1179655A1 (zh) 2004-05-26 2013-06-09 用於治療癌症的嵌合腺病毒
HK15106084.7A HK1205529A1 (zh) 2004-05-26 2015-06-26 用於治療癌症的嵌合腺病毒

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07112859.8A HK1109421A1 (en) 2004-05-26 2007-11-26 Chimeric adenoviruses for use in cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15106084.7A HK1205529A1 (zh) 2004-05-26 2015-06-26 用於治療癌症的嵌合腺病毒

Country Status (33)

Country Link
US (6) US7510868B2 (zh)
EP (1) EP1749098B1 (zh)
JP (1) JP4787936B2 (zh)
KR (1) KR101169109B1 (zh)
CN (3) CN102816742B (zh)
AR (2) AR049188A1 (zh)
AT (1) ATE491799T1 (zh)
AU (1) AU2005250396B2 (zh)
BR (2) BRPI0510475B8 (zh)
CA (2) CA2567094C (zh)
CR (1) CR8794A (zh)
DE (1) DE602005025340D1 (zh)
DK (1) DK1749098T3 (zh)
EC (1) ECSP067088A (zh)
ES (1) ES2358204T3 (zh)
GT (1) GT200500129A (zh)
HK (3) HK1109421A1 (zh)
HR (1) HRP20110179T1 (zh)
IL (2) IL179098A (zh)
MX (1) MXPA06013570A (zh)
MY (1) MY140829A (zh)
NO (1) NO340708B1 (zh)
NZ (1) NZ551443A (zh)
PA (1) PA8634201A1 (zh)
PE (1) PE20060277A1 (zh)
PL (1) PL1749098T3 (zh)
PT (1) PT1749098E (zh)
RU (1) RU2448157C2 (zh)
TW (1) TWI366603B (zh)
UA (1) UA89957C2 (zh)
UY (1) UY28926A1 (zh)
WO (1) WO2005118825A2 (zh)
ZA (1) ZA200610763B (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101169109B1 (ko) 2004-05-26 2012-07-26 싸이오서스 테라퓨틱스 엘티디. 암 치료에 사용하기 위한 키메릭 아데노바이러스
WO2007130604A2 (en) * 2006-05-04 2007-11-15 Baylor Research Institute Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
CA2667414C (en) 2006-11-13 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the human glucocorticoid receptor locus
JP5448840B2 (ja) * 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
KR100856310B1 (ko) 2007-02-28 2008-09-03 삼성전기주식회사 이동통신 단말기
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
EP2827895B1 (en) * 2012-03-22 2017-08-09 Janssen Vaccines & Prevention B.V. Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CA2902650A1 (en) * 2013-02-28 2014-09-04 Psioxus Therapeutics Limited A process for the production of adenovirus
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
AU2014280123B2 (en) 2013-06-14 2019-11-14 Akamis Bio Limited A dosing regime and formulations for type B adenoviruses
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB2531821A (en) * 2013-10-25 2016-05-04 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201415579D0 (en) 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
KR20170044194A (ko) 2014-08-27 2017-04-24 싸이오서스 테라퓨틱스 엘티디. 아데노바이러스의 제조를 위한 공정
AU2016256582B2 (en) * 2015-04-30 2020-10-29 Akamis Bio Limited Oncolytic adenovirus encoding a B7 protein
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CN109790530A (zh) * 2016-07-25 2019-05-21 埃森德生物制药有限公司 治疗癌症的方法
EP4273252A3 (en) 2016-08-29 2024-04-17 Akamis Bio Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
US11142580B2 (en) 2017-06-01 2021-10-12 Psioxus Therapeutics Limited Oncolytic virus and method
US11981723B2 (en) 2017-09-05 2024-05-14 GLAdiator Biosciences, Inc. Method of targeting exosomes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EP3906038A4 (en) 2018-11-21 2022-06-01 Mayo Foundation for Medical Education and Research ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS
CA3138527C (en) 2019-04-29 2024-03-12 Mayo Foundation For Medical Education And Research Multivalent pd-l1 binding compounds for treating cancer
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
JP4190028B2 (ja) 1993-07-13 2008-12-03 アベンテイス・フアルマ・ソシエテ・アノニム 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
AU777041B2 (en) * 1999-05-17 2004-09-30 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
EP1083228A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
JP2003534806A (ja) * 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
DE60234496D1 (de) * 2001-01-04 2010-01-07 Goeran Wadell Virusvektor zur gentherapie
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
KR101169109B1 (ko) 2004-05-26 2012-07-26 싸이오서스 테라퓨틱스 엘티디. 암 치료에 사용하기 위한 키메릭 아데노바이러스
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用

Also Published As

Publication number Publication date
ZA200610763B (en) 2009-06-24
PT1749098E (pt) 2011-02-02
PA8634201A1 (es) 2006-11-09
US20130230902A2 (en) 2013-09-05
IL226820A (en) 2017-07-31
PL1749098T3 (pl) 2011-05-31
MXPA06013570A (es) 2007-02-08
BR122013008865B1 (pt) 2020-11-24
CR8794A (es) 2007-08-28
US20120231524A1 (en) 2012-09-13
CA2567094C (en) 2014-11-25
US8158599B2 (en) 2012-04-17
HK1205529A1 (zh) 2015-12-18
US20090227000A1 (en) 2009-09-10
CN104263703B (zh) 2018-01-09
US7510868B2 (en) 2009-03-31
KR20070020302A (ko) 2007-02-20
BRPI0510475B8 (pt) 2021-05-25
CN102816742A (zh) 2012-12-12
NZ551443A (en) 2010-01-29
HRP20110179T1 (hr) 2011-04-30
MY140829A (en) 2010-01-29
AR090647A2 (es) 2014-11-26
US20150037874A1 (en) 2015-02-05
CA2567094A1 (en) 2005-12-15
CN104263703A (zh) 2015-01-07
CA2836987A1 (en) 2005-12-15
US9115337B2 (en) 2015-08-25
BR122013008865B8 (pt) 2021-05-25
CN104263703B9 (zh) 2019-12-17
US20130209409A1 (en) 2013-08-15
US20050265973A1 (en) 2005-12-01
US9034344B2 (en) 2015-05-19
RU2006145071A (ru) 2008-07-10
ECSP067088A (es) 2007-01-26
EP1749098B1 (en) 2010-12-15
UY28926A1 (es) 2006-01-31
DE602005025340D1 (de) 2011-01-27
ES2358204T3 (es) 2011-05-06
TWI366603B (en) 2012-06-21
US20130217095A1 (en) 2013-08-22
EP1749098A2 (en) 2007-02-07
ATE491799T1 (de) 2011-01-15
DK1749098T3 (da) 2011-04-04
CN1997746A (zh) 2007-07-11
AR049188A1 (es) 2006-07-05
NO20066002L (no) 2006-12-22
WO2005118825A3 (en) 2006-11-23
PE20060277A1 (es) 2006-05-25
NO340708B1 (no) 2017-06-06
AU2005250396A1 (en) 2005-12-15
CA2836987C (en) 2016-07-05
JP4787936B2 (ja) 2011-10-05
WO2005118825A2 (en) 2005-12-15
KR101169109B1 (ko) 2012-07-26
JP2008500051A (ja) 2008-01-10
CN1997746B (zh) 2012-09-26
GT200500129A (es) 2006-03-23
US8765463B2 (en) 2014-07-01
TW200611974A (en) 2006-04-16
BRPI0510475B1 (pt) 2020-09-29
IL226820A0 (en) 2013-07-31
CN102816742B (zh) 2014-04-09
BRPI0510475A (pt) 2007-11-06
UA89957C2 (ru) 2010-03-25
IL179098A (en) 2015-09-24
US9234185B2 (en) 2016-01-12
HK1109421A1 (en) 2008-06-06
IL179098A0 (en) 2007-03-08
AU2005250396B2 (en) 2010-11-11
RU2448157C2 (ru) 2012-04-20

Similar Documents

Publication Publication Date Title
HK1205529A1 (zh) 用於治療癌症的嵌合腺病毒
HK1201182A1 (zh) 用於治療癌症或腫瘤的聚乙二醇化的
HK1136822A1 (en) Therapeutic compounds and their use in cancer
EP1814544A4 (en) CANCER TREATMENTS
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
EP1747284A4 (en) DIAGNOSTICS AND THERAPEUTICS OF CANCER
EP1830847A4 (en) CANCER TREATMENT
EP2023950A4 (en) CANCER TREATMENT WITH URODILATIN
IL185258A (en) Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
GB0400700D0 (en) Compounds useful in therapy
HK1151971A1 (en) Compounds for use in the treatment of cancer
GB0428187D0 (en) Cancer treatment
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
GB0413346D0 (en) Treating cancer
GB0507685D0 (en) Cancer treatment
GB0404675D0 (en) Cancer treatment
GB0516610D0 (en) Compounds for use in therapy
GB0522671D0 (en) Spisulosine compounds for use in cancer therapy
GB0803201D0 (en) Two-part dressing suitable for use in surgery
GB0427826D0 (en) Compounds for use in therapy
GB0423117D0 (en) Compounds for use in therapy
GB0604794D0 (en) Spisulosine compounds for use in cancer therapy